Company intelligence / Profile preview

HUITAI Biomedicine

Ownership: Private
Development stage: Other

Overview

HUITAI’s lead asset, HTPEP‑001, a first-in-class synthetic peptide that antagonizes the interaction between thrombospond‑1 and CD36 to block activation of TGF‑β1, has completed a Phase I clinical trial in China for idiopathic pulmonary fibrosis. The trial showed encouraging safety results with no systemic adverse effects or common inhalation side effects. The company plans to submit an IND application to the FDA for further development. Additional pipeline programs are at preclinical stage targeting liver cirrhosis and other fibrotic diseases[2][3][6].

Therapeutic areas: PulmonologyDermatologyGastroenterologyOncologyNephrology
Modalities: Synthetic peptide
Industry: Biotech

Drug pipeline

6 assets

HTPEP-002

Preclinical

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on HUITAI Biomedicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUITAI Biomedicine.

Explore the full profile